Boston Trust Walden Corp Raises Holdings in The Cooper Companies, Inc. $COO

Key Points

• Boston Trust Walden Corp increased its stake in The Cooper Companies, Inc. by 1.9% during the second quarter, owning 1,465,621 shares valued at approximately $104.3 million.
• Cooper Companies announced a $2 billion share repurchase program, which allows it to buy back up to 15.4% of its stock, typically indicating that the management believes the shares are undervalued.
• The company's quarterly earnings exceeded expectations, reporting $1.10 per share, up from $0.96 per share a year ago, with revenue hitting $1.06 billion.

Boston Trust Walden Corp grew its position in The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 1.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,465,621 shares of the medical device company's stock after buying an additional 27,644 shares during the quarter. Boston Trust Walden Corp owned 0.73% of Cooper Companies worth $104,294,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in COO. Zions Bancorporation National Association UT purchased a new stake in shares of Cooper Companies in the 1st quarter worth $33,000. GKV Capital Management Co. Inc. purchased a new stake in shares of Cooper Companies during the 1st quarter worth $40,000. Larson Financial Group LLC lifted its stake in shares of Cooper Companies by 1,071.0% during the 1st quarter. Larson Financial Group LLC now owns 726 shares of the medical device company's stock worth $61,000 after purchasing an additional 664 shares during the last quarter. HM Payson & Co. lifted its stake in shares of Cooper Companies by 147.4% during the 1st quarter. HM Payson & Co. now owns 893 shares of the medical device company's stock worth $75,000 after purchasing an additional 532 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its stake in shares of Cooper Companies by 33.7% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,191 shares of the medical device company's stock worth $85,000 after purchasing an additional 300 shares during the last quarter. 24.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on COO shares. Mizuho decreased their price objective on Cooper Companies from $105.00 to $90.00 and set an "outperform" rating for the company in a research note on Wednesday, July 16th. Stifel Nicolaus decreased their price target on Cooper Companies from $90.00 to $85.00 and set a "buy" rating for the company in a research note on Thursday, August 28th. Needham & Company LLC reiterated a "buy" rating and issued a $94.00 price target on shares of Cooper Companies in a research note on Thursday, August 28th. Morgan Stanley set a $76.00 price target on Cooper Companies and gave the company an "equal weight" rating in a research note on Thursday, August 28th. Finally, JPMorgan Chase & Co. decreased their price target on Cooper Companies from $76.00 to $66.00 and set a "neutral" rating for the company in a research note on Thursday, August 28th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $84.77.

Cooper Companies Stock Up 1.4%

Cooper Companies stock opened at $69.30 on Tuesday. The firm has a market cap of $13.78 billion, a price-to-earnings ratio of 34.14, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The Cooper Companies, Inc. has a 52 week low of $61.78 and a 52 week high of $109.37. The business's 50-day moving average price is $69.39 and its 200 day moving average price is $73.48. The company has a quick ratio of 1.24, a current ratio of 2.12 and a debt-to-equity ratio of 0.29.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its quarterly earnings results on Wednesday, August 27th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to the consensus estimate of $1.06 billion. Cooper Companies had a return on equity of 9.82% and a net margin of 10.08%.Cooper Companies's revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 17th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 15.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, EVP Brian G. Andrews purchased 1,525 shares of the stock in a transaction on Tuesday, September 2nd. The shares were bought at an average price of $65.68 per share, for a total transaction of $100,162.00. Following the completion of the transaction, the executive vice president owned 22,191 shares of the company's stock, valued at $1,457,504.88. This trade represents a 7.38% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of the stock in a transaction on Monday, September 29th. The shares were acquired at an average price of $68.39 per share, for a total transaction of $136,780.00. Following the transaction, the director directly owned 5,777 shares of the company's stock, valued at $395,089.03. This represents a 52.95% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 17,975 shares of company stock valued at $1,216,346 in the last ninety days. 1.98% of the stock is currently owned by company insiders.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.